Dr. Ruben Mesa (Executive Director of the Wake Forest Baptist Comprehensive Cancer Center) joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelanc...
All content for The Lancet Haematology in conversation with is the property of The Lancet Group and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr. Ruben Mesa (Executive Director of the Wake Forest Baptist Comprehensive Cancer Center) joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelanc...
Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML
The Lancet Haematology in conversation with
14 minutes
1 year ago
Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML
Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00065-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/...
The Lancet Haematology in conversation with
Dr. Ruben Mesa (Executive Director of the Wake Forest Baptist Comprehensive Cancer Center) joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelanc...
